Urological Research

, Volume 35, Issue 2, pp 55–62 | Cite as

Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function

  • Markus Jaggi
  • Yasushi Nakagawa
  • Ljerka Zipperle
  • Bernhard Hess
Original Paper


Tamm-Horsfall protein (THP) powerfully inhibits calcium oxalate crystal aggregation, but structurally abnormal THPs from recurrent calcium stone formers may promote crystal aggregation. Therefore, increased urinary excretion of abnormal THP might be of relevance in nephrolithiasis. We studied 44 recurrent idiopathic calcium stone formers with a positive family history of stone disease (RCSFfam) and 34 age- and sex-matched healthy controls (C). Twenty-four-hour urinary THP excretion was measured by enzyme linked immunosorbent assay. Structural properties of individually purified THPs were obtained from analysis of elution patterns from a Sepharose 4B column. Sialic acid (SA) contents of native whole 24-h urines, crude salt precipitates of native urines and individually purified THPs were measured. THP function was studied by measuring inhibition of CaOx crystal aggregation in vitro (pH 5.7, 200 mM sodium chloride). Twenty-four-hour urine excretion of THP was higher in RCSFfam (44.0 ± 4.0 mg/day) than in C (30.9 ± 2.2 mg/day, P = 0.015). Upon salt precipitation and lyophilization, elution from a Sepharose 4B column revealed one major peak (peak A, cross-reacting with polyclonal anti-THP antibody) and a second minor peak (peak B, not cross-reacting). THPs from RCSFfam eluted later than those from C (P = 0.021), and maximum width of THP peaks was higher in RCSFfam than in C (P = 0.024). SA content was higher in specimens from RCSFfam than from C, in native 24-h urines (207.5 ± 20.4 mg vs. 135.2 ± 16.1 mg, P = 0.013) as well as in crude salt precipitates of 24-h urines (10.4 ± 0.5 mg vs. 7.4 ± 0.9 mg, P = 0.002) and in purified THPs (75.3 ± 9.3 μg/mg vs. 48.8 ± 9.8 μg/mg THP, P = 0.043). Finally, inhibition of calcium oxalate monohydrate crystal aggregation by 40 mg/L of THP was lower in RCSFfam (6.1 ± 5.5%, range −62.0 to +84.2%) than in C (24.9 ± 6.0%, range −39.8 to +82.7%), P = 0.022, and only 25 out of 44 (57%) THPs from RCSFfam were inhibitory (positive inhibition value) vs. 25 out of 34 (74%) THPs from C, P < 0.05. In conclusion, severely recurrent calcium stone formers with a positive family history excrete more THP than healthy controls, and their THP molecules elute later from an analytical column and contain more SA. Such increasingly aggregated THP molecules predispose to exaggerated calcium oxalate crystal aggregation, an important prerequisite for urinary stone formation.


Nephrolithiasis Positive family history Calcium oxalate Tamm-Horsfall protein Sialic acid Crystal aggregation inhibition 



The study was partly supported by the Swiss National Science Foundation (Grant 32-43448.95) and by PHSN/NIDDK (grant DK 56788-06).


  1. 1.
    Kumar S, Muchmore A (1990) Tamm-Horsfall protein—Uromodulin (1950–1990). Kidney Int 37:1395–1401PubMedGoogle Scholar
  2. 2.
    Serrafini-Cessi F, Malagolini N, Cavallone D (2003) Tamm-Horsfall glycoprotein: biology and clinical relevance. Am J Kidney Dis 42:658–676CrossRefGoogle Scholar
  3. 3.
    Pak J, Pu Y, Zjang Z-T, Hasty DL, Wu X-R (2001) Tamm-Horsfall protein binds to type 1 fimbriated Escherichia coli and prevents E. coli from binding to uroplakin Ia and Ib receptors. J Biol Chem 276:9924–9930PubMedCrossRefGoogle Scholar
  4. 4.
    Bates JM, Raffi HM, Prasadan K, Mascarenhas R, Laszik Z, Maeda N, Hultgren SJ, Kumar S (2004) Tamm-Horsfall protein knockout mice are more prone to urinary tract infection: rapid communication. Kidney Int 65:791–797PubMedCrossRefGoogle Scholar
  5. 5.
    Wimmer T, Cohen G, Saemann MD, Hörl WH (2004) Effects of Tamm-Horsfall protein on polymorphonuclear leukocyte function. Nephrol Dial Transplant 19:2192–2197PubMedCrossRefGoogle Scholar
  6. 6.
    Mo L, Huang H-Y, Zhu X-H, Shapiro E, Hasty DL, Wu X-R (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166PubMedCrossRefGoogle Scholar
  7. 7.
    Hess B, Kok DJ (1996) Nucleation, growth and aggregation of stone-forming crystals. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management, Chap. 1. Lippincott-Raven Publishers, PhiladelphiaGoogle Scholar
  8. 8.
    Fleisch H (1987) Inhibitors and promoters of stone formation. Kidney Int 13:361–371Google Scholar
  9. 9.
    Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46:847–854PubMedGoogle Scholar
  10. 10.
    Khan SR (1997) Tubular surface events during nephrolithiasis. Curr Opin Urol 7:240–247CrossRefGoogle Scholar
  11. 11.
    Scurr DS, Robertson WG (1986) Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. J Urol 136:128–131PubMedGoogle Scholar
  12. 12.
    Hess B (1994) Tamm-Horsfall glycoprotein and calcium nephrolithiasis. Miner Electrolyte Metab 20:393–398PubMedGoogle Scholar
  13. 13.
    Hess B, Nakagawa Y, Coe FL (1989) Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol 257:F99–F106PubMedGoogle Scholar
  14. 14.
    Hess B, Zipperle L, Jaeger Ph (1993) Citrate and calcium effects on Tamm-Horsfall glycoprotein as a modifier of calcium oxalate crystal aggregation. Am J Physiol 265:F784–F791PubMedGoogle Scholar
  15. 15.
    Hess B, Nakagawa Y, Parks JH, Coe FL (1991) Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 260:F569–F578PubMedGoogle Scholar
  16. 16.
    Knörle R, Schnierle P, Koch A, Buchholz N-P, Hering F, Seiler H, Ackermann T, Rutishauser G (1994) Tamm-Horsfall glycoprotein: role in inhibition and promotion of renal calcium oxalate stone formation studied with Fourier-transform infrared spectrometry. Clin Chem 40:1739–1743PubMedGoogle Scholar
  17. 17.
    Glauser A, Hochreiter W, Jaeger Ph, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 14:1580–1587CrossRefGoogle Scholar
  18. 18.
    Reinhart HH, Obedeanu N, Walz D, Sobel JD (1989). A new ELISA method for the rapid quantification of Tamm-Horsfall protein in urine. Am J Pathol 92:199–205Google Scholar
  19. 19.
    Fletcher AP, Neuberger A, Ratcliffe WA (1970) Tamm-Horsfall urinary glycoprotein: the chemical composition. Biochem J 120:417–424PubMedGoogle Scholar
  20. 20.
    Aminoff D (1961) Method for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem J 81:384–392PubMedGoogle Scholar
  21. 21.
    Bichler KH, Kirchner Ch, Ideler V (1976) Uromucoid excretion in normal individuals and stone formers. Br J Urol 47:733–738CrossRefGoogle Scholar
  22. 22.
    Samuell CT (1979) Uromucoid excretion in normal subjects, calcium stone formers and in patients with chronic renal failure. Urol Res 7:5–12PubMedCrossRefGoogle Scholar
  23. 23.
    Thornley C, Dawnay A, Cattell WR (1985) Human Tamm-Horsfall glycoprotein: urinary and plasma levels in normal subjects and patients with renal disease determined by a fully validated radioimmunoassay. Clin Sci 68:529–535PubMedGoogle Scholar
  24. 24.
    Erwin DT, Kok DJ, Alam J, et al (1994) Calcium oxalate stone agglomeration reflects stone forming activity: citrate inhibition depends on macromolecules larger than 30 kilodaltons. Am J Kidney Dis 24:893–900PubMedGoogle Scholar
  25. 25.
    Romero MC, Nocera S, Nesse AB (1997) Decreased Tamm-Horsfall protein in lithiasic patients. Clin Biochem 30:63–67PubMedCrossRefGoogle Scholar
  26. 26.
    Ganter K, Bongartz D, Hesse A (1999) Tamm-Horsfall protein excretion and its relation to citrate in urine of stone-forming patients. Urology 53:492–495PubMedCrossRefGoogle Scholar
  27. 27.
    Bichler KH, Mittermüller B, Strohmaier WL, Feil G, Eipper E (1999) Excretion of Tamm-Horsfall protein in patients with uric acid stones. Urol Int 62:87–92PubMedCrossRefGoogle Scholar
  28. 28.
    Sumitra K, Pragasam V, Sakthivel R, Kalaiselvi P, Varalakshmi P (2005) Beneficial effects of vitamin E supplementation on the biochemical and kinetic properties of Tamm-Horsfall glycoprotein in hypertensive and hyperoxaluric subjects. Nephrol Dial Transplant 20:1407–1415PubMedCrossRefGoogle Scholar
  29. 29.
    Khan SR (2004) Role of renal epithelial cells in the initiation of calcium oxalate stones. Nephron Exp Nephrol 98:e55–e60PubMedCrossRefGoogle Scholar
  30. 30.
    Coe FL, Evan A, Worcester E (2005) Kidney stone disease. J Clin Invest 115:2598–2608PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Markus Jaggi
    • 1
    • 3
  • Yasushi Nakagawa
    • 2
  • Ljerka Zipperle
    • 1
  • Bernhard Hess
    • 1
    • 4
  1. 1.Renal Stone Clinic and Stone Research Laboratory, Policlinic of Internal MedicineUniversity HospitalBerneSwitzerland
  2. 2.Kidney Stone LaboratoryUniversity of ChicagoChicagoUSA
  3. 3.Department of AnesthesiologyKantonsspitalLucerneSwitzerland
  4. 4.Internal Medicine and NephrologyKlinik Im ParkZurichSwitzerland

Personalised recommendations